What is the official website of Sandoz Hungária ?

The official website of Sandoz Hungária is https://www.sandoz.hu/.

What is Sandoz Hungária's cybersecurity risk score?

Sandoz Hungária has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Sandoz Hungária experienced?

According to Rankiteo, Sandoz Hungária currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Sandoz Hungária been affected by any supply chain cyber incidents ?

According to Rankiteo, Sandoz Hungária has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Sandoz Hungária have SOC 2 Type 1 certification ?

According to Rankiteo, Sandoz Hungária is not certified under SOC 2 Type 1.

Does Sandoz Hungária have SOC 2 Type 2 certification ?

According to Rankiteo, Sandoz Hungária does not hold a SOC 2 Type 2 certification.

Does Sandoz Hungária comply with GDPR ?

According to Rankiteo, Sandoz Hungária is not listed as GDPR compliant.

Does Sandoz Hungária have PCI DSS certification ?

According to Rankiteo, Sandoz Hungária does not currently maintain PCI DSS compliance.

Does Sandoz Hungária comply with HIPAA ?

According to Rankiteo, Sandoz Hungária is not compliant with HIPAA regulations.

Does Sandoz Hungária have ISO 27001 certification ?

According to Rankiteo,Sandoz Hungária is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Sandoz Hungária operate in ?

Sandoz Hungária operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Sandoz Hungária have ?

Sandoz Hungária employs approximately 34 people worldwide.

Does Sandoz Hungária own any subsidiaries ?

Sandoz Hungária presently has no subsidiaries across any sectors.

How many LinkedIn followers does Sandoz Hungária have ?

Sandoz Hungária's official LinkedIn profile has approximately 806 followers.

What is the NAICS classification code for Sandoz Hungária ?

Sandoz Hungária is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Sandoz Hungária have a Crunchbase profile ?

No, Sandoz Hungária does not have a profile on Crunchbase.

Does Sandoz Hungária have a LinkedIn profile ?

Yes, Sandoz Hungária maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/sandozhungaria.

How many cybersecurity incidents has Sandoz Hungária experienced ?

As of September 17, 2026, Rankiteo reports that Sandoz Hungária has not experienced any cybersecurity incidents.

How many peer or competitor companies does Sandoz Hungária have ?

Sandoz Hungária has an estimated 5,766 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Sandoz Hungária

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Sandoz Hungária Vendor Cyber Rating & Cyber Score

sandoz.hu

Add Your Compliance Badge

A Sandoz egy gyógyszeripari vállalat, mely meghatározó szerepet tölt be a generikus és a biohasonló gyógyszerek nemzetközi piacán. A Sandoznál több mint egy évszázada kutatunk, fejlesztünk és biztosítunk olyan gyógyszereket, amelyek világszerte milliók életét teszik jobbá és hosszabbítják meg. Több mint 1000 molekulából álló és egyre bővülő portfóliónkkal mi vagyunk a legnagyobb generikus vállalat Európában, globálisan a második legnagyobb, célunk pedig az, hogy a világ vezető generikusgyógyszer-gyártó vállalata legyünk. Széles portfóliónk élén a piacvezető biohasonló gyógyszerek és generikus antibiotikumok állnak, amelyek a globális egészségügy alapját képezik, s melyek jelentős és folyamatos megtakarítást jelentenek az egészségügyi

Sandoz Hungária

Sandoz Hungária CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Sandoz Hungária Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Sandoz Hungária

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz Hungária in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Sandoz Hungária in 2026.

Incident Types Sandoz Hungária vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz Hungária in 2026.

Incident History - Sandoz Hungária (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Sandoz Hungária Subsidiaries

Sandoz Hungária

Pharmaceutical Manufacturing

Website: https://www.sandoz.hu/

Company Size: 51-200 employees

SandozPharmaceutical Manufacturing

Sandoz EgyptPharmaceutical Manufacturing

Sandoz MéxicoPharmaceutical Manufacturing

Sandoz BelgiumPharmaceutical Manufacturing

Sandoz SverigePharmaceutical Manufacturing

Sandoz ItaliaPharmaceutical Manufacturing

Sandoz ÖsterreichPharmaceutical Manufacturing

Sandoz do BrasilFabricação de produtos farmoquímicos e farmacêuticos

Lek PharmaceuticalsPharmaceutical Manufacturing

Sandoz FrancePharmaceutical Manufacturing

Sandoz SrbijaPharmaceutical Manufacturing

Sandoz PolskaPharmaceutical Manufacturing

Sandoz Czech RepublicPharmaceutical Manufacturing

Sandoz HrvatskaPharmaceutical Manufacturing

Sandoz CanadaPharmaceutical Manufacturing

Sandoz UK & IrelandPharmaceutical Manufacturing

Life at SandozArzneimittelherstellung

Sandoz RomaniaPharmaceutical Manufacturing

Sandoz India Pvt LtdPharmaceutical Manufacturing

Sandoz Australia & New ZealandPharmaceutical Manufacturing

Sandoz in DeutschlandPharmaceutical Manufacturing

Sandoz IberiaPharmaceutical Manufacturing

Sandoz NederlandPharmaceutical Manufacturing

Sandoz DanmarkPharmaceutical Manufacturing

Loading…

Sandoz Hungária Similar Companies

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Loading…

NEWS

Sandoz Hungária CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-65388

SUMMARY

A remote attacker who controls a container registry may be able to direct a client's token request to a host of the attacker's choice, and disclose the victim's registry credentials to that host. This vulnerability is addressed in containerization version 0.41.0.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/apple/containerization/security/advisories/GHSA-mx96-5vvg-x2mg

CVE-2026-61599

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the djust live transport resolves the LiveView to mount from a client-supplied dotted path by calling `__import__(module_path, ...)`. The module is imported — running its top-level code (import side effects) — before the framework checks that the resolved object is a `LiveView` subclass and before any per-view authentication. The `LIVEVIEW_ALLOWED_MODULES` allowlist that should contain this is fail-open (`if allowed_modules:` — skipped when the setting is unset, the framework default) and uses loose `startswith` matching. An unauthenticated WebSocket client (the WS handshake does not require auth; per-view auth runs only after import + instantiate) can therefore send a `mount` / `live_redirect_mount` / `url_change` frame (or an SSE mount) with `view = "<any.importable.module>.AnyName"` and cause the server to import — and execute the top-level code of — any importable Python module by name. Version 1.0.7 fixes the issue with a fail-closed resolution gate (`djust._view_resolution.is_view_import_allowed`): a client view path resolves only if (a) its module is already loaded (`sys.modules` — so resolving runs no new code; URL-routed views loaded by URLconf at startup keep working with zero config) or (b) it matches `LIVEVIEW_ALLOWED_MODULES` on a module-segment boundary (explicit opt-in for lazily-imported views). The gate runs before `__import__` at all three sinks (+ defense-in-depth inside `_instantiate_view`). As a workaround, set `LIVEVIEW_ALLOWED_MODULES` to the narrow list of modules that contain your mountable LiveView classes. (Note: pre-patch the allowlist is `startswith`-matched and the import still precedes the subclass check, so this is mitigation, not a complete fix.)

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: )

cvss4

Base Score: 8.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-61596

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, djust's per-object authorization (`get_object` + `has_object_permission`, ADR-017) was enforced on the WebSocket mount and event paths but not on three other render entry points: (a) the initial HTTP GET render, (b) SPA `url_change` navigation, and (c) `{% live_render %}` embedded child views. An authenticated user could therefore view (and on some paths act on) an object they are not authorized for by loading the page directly, navigating to it via SPA url-change, or composing it as an embedded child — a classic IDOR / broken object-level access control on object-scoped views. This is fixed in djust 1.0.7. All render entry points now route through a shared `enforce_object_permission` chokepoint: HTTP GET returns 403, `url_change` emits a `permission_denied` frame and skips the render, and `{% live_render %}` (eager + lazy) refuses the embed. Views without a custom `get_object` are unaffected (no-op). No reliable workaround short of upgrading. Do not expose object-scoped views through the HTTP-GET / url_change / live_render paths until patched.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-61589

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, the WebSocket `handle_mount` and `ViewRuntime._build_request` rebuild an `HttpRequest` via `RequestFactory().get(...)` with no `HTTP_HOST`, so `request.get_host()` defaulted to `"testserver"` on the live path. Host/subdomain/domain `TenantResolver`s then misresolved the tenant — `None` on the live path while the HTTP path resolved correctly. With `STRICT_MODE=False` the tenant-scoped managers returned unscoped rows (cross-tenant disclosure); with the default they returned an empty queryset (broken tenancy). This is fixed in djust 1.0.7. The handshake Host is extracted from the ASGI scope, validated against `ALLOWED_HOSTS` (the same logic as the CSWSH Origin gate, parsed with Django's `split_domain_port` so malformed Hosts are rejected at the boundary), and propagated — with the TLS scheme — into the reconstructed request, so live-path tenant resolution matches HTTP exactly. There is no known workaround on the live path short of upgrading. Users are most exposed when combined with `STRICT_MODE=False`.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 6.3)

cvss3

Base Score: 6.3

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:N/A:N

Impact Score

Exploitability

1.8

REFERENCES

CVE-2026-61588

SUMMARY

djust provides Phoenix LiveView-style reactive server-side rendering for Django with Rust-powered performance. Prior to version 1.0.7, when a Django `Model` instance is assigned to a public view attribute, djust serialized it to the client with no sensitive-field denylist — sending fields such as `password` (the hash), privilege flags (e.g. `is_staff` / `is_superuser`), tokens, and other PII to the browser. Because exposing model objects to templates is a normal djust pattern, this could leak credentials/PII without the developer realizing the full object crossed the wire. This is fixed in djust 1.0.7. Model serialization applies a secure-by-default sensitive-field denylist (password/hash/token/secret-style fields and known privilege flags are withheld) with an identity-subset fallback. As a workaround, keep `Model` instances on `_private` attributes and expose only the specific fields needed, until patched.

Published

Date2026-09-16

Updated

Date2026-09-16

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Sandoz Hungária Vendor Cyber Rating & Cyber Score

Sandoz Hungária A.I CyberSecurity Scoring

Sandoz Hungária CyberSecurity News & History

Sandoz Hungária Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Sandoz Hungária

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Sandoz Hungária vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Sandoz Hungária (X = Date, Y = Severity)

Sandoz Hungária Subsidiaries

Sandoz Hungária

Sandoz Hungária Similar Companies

Cipla

Zydus Group

Glenmark Pharmaceuticals

Eli Lilly and Company

Parexel

Bristol Myers Squibb

Novo Nordisk

Torrent Pharmaceuticals Ltd

Astellas Pharma

Sandoz Hungária CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Sandoz Hungária CyberSecurity News & History

Sandoz Hungária Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Sandoz Hungária

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Sandoz Hungária vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Sandoz Hungária (X = Date, Y = Severity)

Sandoz Hungária Subsidiaries

Sandoz Hungária

Sandoz Hungária Similar Companies

Cipla

Zydus Group

Glenmark Pharmaceuticals

Eli Lilly and Company

Parexel

Bristol Myers Squibb

Novo Nordisk

Torrent Pharmaceuticals Ltd

Astellas Pharma

Sandoz Hungária CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo